Table 3. Serum biomarkers of patients with EGPA based on prednisone usage at time of study visit.

Serum parameters	No pred. use (n = 24)	Pred. use (n = 81)	MWU	LR
Eotaxin-3 [pg/ml]	9.7 (0–549.8)	0 (0–555.5)	0.004	0.021
TARC/CCL17 [pg/ml]	393.6 (129.3–1918.0)	285.5 (77.1–4549.4)	0.18	0.67
IgG4 [mg/dL]	21.5 (7.0–281.0)	47.0 (7.0–479.0)	0.038	0.099
IgG4/IgG ratio*100	3.4 (0.1–22.0)	6.0 (1.0–32.0)	0.52	0.19
ESR [mm/1st hour]	5.0 (1–40.0)	5.0 (1–40)	0.80	0.084
CRP [mg/L]	2.9 (0.1–32.9)	2.2 (0.1–21.0)	0.41	0.20
Eosinophils (%)	8.0 (1–50.0)	4.0 (0.1–43.0)	<0.001	0.006

Data are shown as median (range in parenthesis); EGPA: eosinophilic granulomatosis with polyangiitis (Churg-Strauss); LR, Logistic regression analysis as described in Materials and Methods; MWU, Mann Whitney U test; n, number of visits; pred., prednisone